Get the Stockscreener App
17.65
0.73%
-0.24
Mediwound Ltd stock is traded at $17.65, with a volume of 11,074.
It is down -0.73% in the last 24 hours and up +5.09% over the past month.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
See More
Previous Close:
$17.89
Open:
$17.72
24h Volume:
11,074
Relative Volume:
0.24
Market Cap:
$189.90M
Revenue:
$19.85M
Net Income/Loss:
$-12.75M
P/E Ratio:
-7.2634
EPS:
-2.43
Net Cash Flow:
$-21.94M
1W Performance:
+3.26%
1M Performance:
+5.09%
6M Performance:
+16.69%
1Y Performance:
+72.26%
1-Day Range:
$17.38
$17.90
1-Week Range:
$16.35
$18.00
52-Week Range:
$10.14
$24.00
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDWD
Mediwound Ltd
|
17.76 | 189.90M | 19.85M | -12.75M | -21.94M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.64 | 105.21B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.73 | 78.48B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
630.44 | 37.55B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.60 | 31.19B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.44 | 27.43B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-24 | Reiterated | Maxim Group | Buy |
| Dec-22-22 | Initiated | Maxim Group | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Sep-23-20 | Initiated | BTIG Research | Buy |
| Nov-28-16 | Initiated | Aegis Capital | Buy |
| Aug-17-16 | Initiated | Wells Fargo | Outperform |
| Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
Mediwound Ltd Stock (MDWD) Latest News
Learn to Evaluate (MDWD) using the Charts - Stock Traders Daily
Charles Schwab Investment Management Inc. Decreases Position in MediWound Ltd. (NASDAQ:MDWD) - Defense World
MediWound Approves 2024 Share Incentive Plan to Boost Employee Engagement - TipRanks
MediWound to Host Virtual Key Opinion Leader Event to - GlobeNewswire
MediWound Announces Expert Panel Event: Phase III Trial Plans for Revolutionary Wound Treatment EscharEx - StockTitan
MediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company’s Future - Yahoo Finance
(MDWD) Long Term Investment Analysis - Stock Traders Daily
MetLife Investment Management LLC Acquires New Shares in MediWound Ltd. (NASDAQ:MDWD) - Defense World
MDWD (MediWound) Price-to-Operating-Cash-Flow : (As of Dec. 02, 2024) - GuruFocus.com
FY2024 EPS Estimates for MediWound Lowered by HC Wainwright - MarketBeat
Brokers Offer Predictions for MediWound FY2024 Earnings - Defense World
MediWound (FRA:M8W) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com
Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
HC Wainwright Cuts MediWound (NASDAQ:MDWD) Price Target to $25.00 - MarketBeat
MediWound Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
MediWound Ltd (MDWD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
MediWound Advances Enzymatic Therapeutics Amid Financial Shifts - TipRanks
Mediwound earnings missed by $0.53, revenue fell short of estimates - Investing.com Australia
MediWound: Q3 Earnings Snapshot - The Washington Post
Earnings call: MediWound shows progress in Q3 with FDA nod for NexoBrid - Investing.com
MediWound Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update - The Manila Times
MediWound Q3 Revenue Falls to $4.4M Despite NexoBrid FDA Approval; Cuts 2024 Guidance | MDWD Stock News - StockTitan
What To Expect From MediWound Ltd (MDWD) Q3 2024 Earnings - GuruFocus.com
Where are the Opportunities in (MDWD) - Stock Traders Daily
MediWound (MDWD) to Release Earnings on Tuesday - Defense World
MediWound Ltd.'s (NASDAQ:MDWD) institutional investors lost 10% last week but have benefitted from longer-term gains - Simply Wall St
MediWound to Discuss New Share Incentive Plan - TipRanks
MediWound to Report Third Quarter 2024 Financial Results - GlobeNewswire
MediWound Q3 2024 Earnings Call Scheduled for November 26: What to Expect | MDWD Stock News - StockTitan
99,994 Shares in MediWound Ltd. (NASDAQ:MDWD) Bought by ARK Investment Management LLC - MarketBeat
MediWound Ltd. (NASDAQ:MDWD) is Rosalind Advisors Inc.'s 5th Largest Position - MarketBeat
MediWound (STU:M8W) Financial Strength : 6 (As of Jun. 2024) - GuruFocus.com
How the (MDWD) price action is used to our Advantage - Stock Traders Daily
MediWound Is A Healthy Investment (NASDAQ:MDWD) - Seeking Alpha
MediWound's (NASDAQ:MDWD) investors will be pleased with their stellar 125% return over the last year - Yahoo Finance UK
Rosalind Advisors, Inc. Increases Stake in MediWound Ltd - Yahoo Finance
(MDWD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Interview with the CEO: MediWound Ltd. (NASDAQ:MDWD) - The Wall Street Transcript
MediWound (NASDAQ:MDWD) Rating Reiterated by HC Wainwright - Defense World
Trading (MDWD) With Integrated Risk Controls - Stock Traders Daily
Mediwound Ltd Stock (MDWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):